NZ's PHARMAC calls for proposals on insulin glargine supplies

22 February 2016

New Zealand’s Pharmaceutical Management Agency, PHARMAC, this morning announced is interested in considering any proposals from suppliers of the long-acting insulin preparation, insulin glargine (including biosimilar insulin glargine), including associated delivery devices for the treatment of type 1 and type 2 diabetes mellitus.

Insulin glargine is currently the only long-acting insulin preparation fully subsidized by PHARMAC without any restrictions. Three different presentations of insulin glargine are currently listed in Section B and Part II of Section H of the Pharmaceutical Schedule as follows:

Chemical	Presentation	Pack size and packaging	Pack price ($NZ, excl. GST)	Brand name (Supplier)
Insulin glargine	Inj 100 u per ml, 3 ml	5 cartridges	$94.50*	Lantus (Sanofi-Aventis)
	Inj 100 u per ml, 3 ml	5 disposable pens	$94.50*	Lantus SoloStar (Sanofi-Aventis)
	Inj 100 u per ml, 10 ml	1 vial	$63.00*	Lantus (Sanofi-Aventis)
*Prices are subject to confidential rebates

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK